SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go?
PFE 24.36+0.2%10:08 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Anthony Wong who wrote (7952)6/16/1999 7:15:00 PM
From: Bull-like  Read Replies (2) of 9523
 
Anthony-

I think the problem is where you want to put expectation. WLA certainly needs Pfizer's marketing muscle, otherwise lipitor won't be such a huge success. Keep it in mind that very few drugs can be compared to lipitor, and a big reason it IS successful is this coalition with Pfizer. So, WLA did the right thing not to sever the relation with PFE. Now, from hindsight, WLA could have asked for a better deal before they asked PFE for co-marketing lipitor. But right now, what keeps WLA in good financial shape is due largely to Lipitor. We still don't know the impact of Smith-Kline on Rezeulin yet. My feeling is that the competition will dampen the growth, but not the product, of Rezulin. All in all, I still think WLA is in much better shape than most of the big-pharmas and well-positioned for the next pipeline burst in the years ahead. And what buys them time is LIPITOR! For that matter, I think MRK is in serious trouble. Remember, in this industry, PATENTS are the keys!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext